By Novo Nordisk…
Novo Nordisk Pharmatech brings insights on insulin in media development to Cell Series UK virtual conferences
Koege, Denmark: – World-leading cGMP Human Insulin AF and Quats specialist Novo Nordisk Pharmatech A/S will make its debut at Oxford Global’s flagship Cell Series UK combined conferences.
The 9th Cell Series, combining the 9th Annual Cell Culture & Bioprocessing Congress, 7th Annual Regenerative Medicine & Advanced Therapy Development Congress and 6th Annual Cell & Gene Therapy Manufacturing Congress, has been re-imagined as a virtual online event in view of the COVID-19 emergency.
Recombinant insulin in DoE
Novo Nordisk Pharmatech will play a prominent role as a sponsor of the event and contributing to the Cell Culture and Bioprocessing conference track on Cell Media with a presentation: Why Use Recombinant Insulin in DoE For Your Media Development?
The presentation will feature a case study by the University of Barcelona based on the use of a DOE model for determining optimal levels of nutrients in cell culture media for CHO-S cells., as well as examine the use of human insulin in association with CHO cells to produce mabs and also with HEK-293 cells to replicate influenza virus antigens for vaccines.
About Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S was established in 1949, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. Novo Nordisk Pharmatech A/S is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharma and biopharmaceutical industries.
About Cell Series UK 2020
Oxford Global’s flagship Cell Series UK annual event combines three conferences: the Cell Culture & Bioprocessing Congress, the Regenerative Medicine & Advanced Therapy Development Congress and the Cell & Gene Therapy Manufacturing Congress.
Due to the COVID-19 pandemic, the conference will be staged as a virtual online event over two days, opening October 6, which will feature more than 110 presentations and has already attracted some 800 online participants.
The event will offer valuable insights into the latest cell-based research, from cell line development and bioprocessing through to innovation in stem cell therapies, along with a fully immersive experience featuring a programme of Live & OnDemand presentations and group discussions, alongside informal chat & networking opportunities and a highly interactive exhibitor hall.
The event will also feature a variety of interactive roundtable and panel discussions, alongside a host of new virtual content.
The event is organized by Oxford Global with further information at: https://www.oxfordglobal.co.uk/cell-series-uk-virtual/.
Click on Applications for recombinant Insulin Human AF for further details.